страховая часть пенсии расчетный пенсионный капитал
Главное меню:
Интересное
страховая часть пенсии расчетный пенсионный капитал, FDA Approves Brekiya (dihydroergotamine mesylate) Injection , Amneal Receives U.S. FDA Approval for Brekiya® - GlobeNewswire, Brekiya Approved for Acute Treatment of Migraine and Cluster , Best New Migraine Medications and Treatments — Migraine Again, Amneal Pharmaceuticals, Inc. - Amneal Receives U.S. FDA , , .
“We are thrilled to offer the first and only ready-to-use autoinjector for patients suffering from acute and cluster headaches,” said Joe Renda, Senior Vice President, Chief Commercial Officer, Specialty, Amneal. “Physicians are familiar with [dihydroergotamine], which is an effective and well-established therapy that provides sustained relief for . Our single-dose autoinjector represents an innovative therapeutic option for patients that allows for quick self-administration of the medication during these painful attacks without visiting the emergency room.”, BRIDGEWATER, N.J., May 15, 2025 -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved Brekiya (dihydroergotamine mesylate) injection, the first and only dihydroergotamine (DHE) autoinjector for the acute treatment of migraine with or , DHE can be used at any point during a migraine attack, and may protect patients from headache recurrence. 1, 3,4 Approximately 39 million Americans are living with migraine 7, and up to one .
The FDA has approved Brekiya (dihydroergotamine mesylate) injection for the acute treatment of migraine with or without aura and the acute treatment of cluster headaches in adults., In April 2025, the FDA approved the first prescription-based digital therapeutic for episodic migraine prevention. Click Therapeutics’ CT-132 is a 12-week app-based intervention that integrates multiple evidence–based behavioral techniques, including elements of cognitive behavioral therapy (CBT) ., Brekiya ® becomes the first and only DHE autoinjector that allows patients to self-administer the same medication used in hospitals in a ready-to-use form Product will be available for appropriate patients in the second half of 2025 BRIDGEWATER, N.J., May 15, 2025 (GLOBE NEWSWIRE) - Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that the U.S , , , .